Evidence map›Paper›PMID 35459671›Full record

ArticleBMJ open2022

NeuroBlu, an electronic health record (EHR) trusted research environment (TRE) to support mental healthcare analytics with real-world data.

Rashmi Patel, Soon Nan Wee, Rajagopalan Ramaswamy, Simran Thadani, Jesisca Tandi, Ruchir Garg, Nathan Calvanese, Matthew Valko, A John Rush, Miguel E Rentería and 2 more

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Rashmi PatelHolmusk Technologies Inc, New York, New York, USA rashmi.patel@holmusk.com.ORCID 0000-0002-9259-8788
Soon Nan WeeHolmusk Technologies Inc, New York, New York, USA.
Rajagopalan RamaswamyHolmusk Technologies Inc, New York, New York, USA.
Simran ThadaniHolmusk Technologies Inc, New York, New York, USA.
Jesisca TandiHolmusk Technologies Inc, New York, New York, USA.
Ruchir GargHolmusk Technologies Inc, New York, New York, USA.
Nathan CalvaneseHolmusk Technologies Inc, New York, New York, USA.
Matthew ValkoHolmusk Technologies Inc, New York, New York, USA.
A John RushCurbstone Consultant LLC, Santa Fe, New Mexico, USA.
Miguel E RenteríaHolmusk Technologies Inc, New York, New York, USA.
Joydeep SarkarHolmusk Technologies Inc, New York, New York, USA.
Scott H KollinsHolmusk Technologies Inc, New York, New York, USA.
Duke University · USKing's College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeNeuroBlu is a real-world data (RWD) repository that contains deidentified electronic health record (EHR) data from US mental healthcare providers operating the MindLinc EHR system. NeuroBlu enables users to perform statistical analysis through a secure web-based interface. Structured data are available for sociodemographic characteristics, mental health service contacts, hospital admissions, International Classification of Diseases ICD-9/ICD-10 diagnosis, prescribed medications, family history of mental disorders, Clinical Global Impression-Severity and Improvement (CGI-S/CGI-I) and Global Assessment of Functioning (GAF). To further enhance the data set, natural language processing (NLP) tools have been applied to obtain mental state examination (MSE) and social/environmental data. This paper describes the development and implementation of NeuroBlu, the procedures to safeguard data integrity and security and how the data set supports the generation of real-world evidence (RWE) in mental health.

participantsAs of 31 July 2021, 562 940 individuals (48.9% men) were present in the data set with a mean age of 33.4 years (SD: 18.4 years). The most frequently recorded diagnoses were substance use disorders (1 52 790 patients), major depressive disorder (1 29 120 patients) and anxiety disorders (1 03 923 patients). The median duration of follow-up was 7 months (IQR: 1.3 to 24.4 months). FINDINGS TO DATE: The data set has supported epidemiological studies demonstrating increased risk of psychiatric hospitalisation and reduced antidepressant treatment effectiveness among people with comorbid substance use disorders. It has also been used to develop data visualisation tools to support clinical decision-making, evaluate comparative effectiveness of medications, derive models to predict treatment response and develop NLP applications to obtain clinical information from unstructured EHR data. FUTURE PLANS: The NeuroBlu data set will be further analysed to better understand factors related to poor clinical outcome, treatment responsiveness and the development of predictive analytic tools that may be incorporated into the source EHR system to support real-time clinical decision-making in the delivery of mental healthcare services.

Indexed as

Major Depressive DisorderMental Health ServicesAdultElectronic Health RecordsFemaleHumansMaleMental HealthNatural Language ProcessingEPIDEMIOLOGYHealth informaticsPSYCHIATRY

Identifiers

PMID35459671
PMCPMC9036423
OpenAlexW4224308601

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.